Our findings therefore identify PRKCQ‐AS1 and MSI2 as important novel co‐factors for MYCN nonamplified neuroblastoma tumorigenesis, and provide novel targets and a novel therapeutic agent for the treatment of MYCN nonamplified neuroblastoma. This evidence concerns the gene PRKCQ and neuroblastoma.